BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 14c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.01), $0.14 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $12.89 million versus the consensus estimate of $21.58 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FirstCash to acquire UK pawn operator Ramsdens for £206 million
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform